Skip to main content
. Author manuscript; available in PMC: 2009 Mar 1.
Published in final edited form as: Pharmacol Res. 2008 Feb 2;57(3):239–246. doi: 10.1016/j.phrs.2008.01.011

Figure 4. Effects of CGRP8–37 and spantide II.

Figure 4

The inhibitory effects of CGRP8–37 (0.1 µM), a selective antagonist of calcitonin gene-related peptide (CGRP) receptor, spantide II (Spa, 0.1 µM), a selective antagonist of neurokinin-1 (NK1) receptor on capsaicin (Cap, 10 µM)–induced changes in renal perfusion pressure (PP), glomerular filtration rate (GFR), urine flow (UF), and sodium excretion (UNaV) in the isolated kidney perfused at a perfusion pressure of 185–190 mmHg. N=5–6. In panel A and C: * p<0.01 vs Con, + p<0.01 vs Cap, # p<0.01 vs CGRP8–37+Cap and Spa+Cap. In panel B and D: * p<0.05 vs Con, + p<0.05 vs Cap, # p<0.05 vs CGRP8–37+Cap and Spa+Cap